Volume 5, Issue 1 (Avicenna Journal of Pharmaceutical Research, Jun 2024)
Avicenna J Pharma Res 2024, 5(1): 10-17 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shams R, Etminaniesfahani M, Mazdeh M, Soltanian A, Nouri F. Evaluation of Rosuvastatin Therapy on CYBB Gene Expression in Patients with Multiple Sclerosis: An Uncontrolled Clinical Trial. Avicenna J Pharma Res 2024; 5 (1) :10-17
URL: http://ajpr1.umsha.ac.ir/article-1-29-en.html
URL: http://ajpr1.umsha.ac.ir/article-1-29-en.html
Rayeheh Shams *1 
, Maryam Etminaniesfahani2 , Mehrdokht Mazdeh3 , Alireza Soltanian4 , Fatemeh Nouri5
, Maryam Etminaniesfahani2 , Mehrdokht Mazdeh3 , Alireza Soltanian4 , Fatemeh Nouri5
1- Pharmaceutical Sciences Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
3- Neurophysiology Research Center, Institute of Neuroscience and Mental Health, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
4- Modeling of Noncommunicable Diseases Research Center, Institute of Health Sciences and Technologies, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
5- Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
3- Neurophysiology Research Center, Institute of Neuroscience and Mental Health, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
4- Modeling of Noncommunicable Diseases Research Center, Institute of Health Sciences and Technologies, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
5- Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (132 Views)
Background and Objective: Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease. MS is a heterogeneous and complex disease with various degrees of progression and treatment responses to routine drugs. Recently, statins have been used for the treatment of MS due to their high efficacy and low side effects. This study aimed to investigate CYBB expression in MS patients undergoing rosuvastatin therapy.
Methods: This study was conducted on MS patients (n=24). Participants received 20 mg/day of rosuvastatin for 90 days. The Expanded Disability Status Scale (EDSS) and CYBB gene expression were measured before and after treatment with rosuvastatin. For gene expression measurement, total ribonucleic acid was isolated from MS patients' blood. After complementary DNA (cDNA) synthesis, qualitative expression level of the CYBB gene was measured by real-time polymerase chain reaction technique (Roche LightCycler® 96). Additional information of patients was obtained and recorded in a checklist. Data were analyzed with statistical software of GraphPad (version 6) and SPSS (version 23) and the significant level was P<0.05.
Results: Participants were 24 MS patients, including 5 (28.2%) males and 19 (79.2%) females with an average age of 44.25±11.12 years. No significant improvement was observed in the EDSS of patients following rosuvastatin therapy (P>0.05). Also, no significant correlation was observed between CYBB expression level and EDSS (P>0.05). CYBB was significantly upregulated in MS patients after rosuvastatin therapy (P < 0.001), while no significant change was observed in the housekeeping gene expression (P>0.05).
Conclusion: The changes in CYBB gene expression occur earlier than any detectable clinical changes, such as those measured by EDSS.
Methods: This study was conducted on MS patients (n=24). Participants received 20 mg/day of rosuvastatin for 90 days. The Expanded Disability Status Scale (EDSS) and CYBB gene expression were measured before and after treatment with rosuvastatin. For gene expression measurement, total ribonucleic acid was isolated from MS patients' blood. After complementary DNA (cDNA) synthesis, qualitative expression level of the CYBB gene was measured by real-time polymerase chain reaction technique (Roche LightCycler® 96). Additional information of patients was obtained and recorded in a checklist. Data were analyzed with statistical software of GraphPad (version 6) and SPSS (version 23) and the significant level was P<0.05.
Results: Participants were 24 MS patients, including 5 (28.2%) males and 19 (79.2%) females with an average age of 44.25±11.12 years. No significant improvement was observed in the EDSS of patients following rosuvastatin therapy (P>0.05). Also, no significant correlation was observed between CYBB expression level and EDSS (P>0.05). CYBB was significantly upregulated in MS patients after rosuvastatin therapy (P < 0.001), while no significant change was observed in the housekeeping gene expression (P>0.05).
Conclusion: The changes in CYBB gene expression occur earlier than any detectable clinical changes, such as those measured by EDSS.
Type of Study: Research |
Subject:
General
Received: 2026/08/25 | Accepted: 2024/06/30 | Published: 2024/06/30
Received: 2026/08/25 | Accepted: 2024/06/30 | Published: 2024/06/30
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
